New pill aims to soothe agitation in Alzheimer's patients
NCT ID NCT06803823
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This study tests an experimental drug called ONO-2020 to see if it can safely reduce agitation in people with Alzheimer's disease dementia. About 90 participants in Japan will receive either the drug or a placebo daily for several weeks. Researchers will measure changes in agitation symptoms and monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGITATION ASSOCIATED WITH ALZHEIMER'S DISEASE DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aburayama Hospital
RECRUITINGFukuoka, Japan
-
Airanomori Hospital
RECRUITINGKagoshima, Japan
-
Aiseikai General Incorporated Foundation, Hirosaki Aiseikai Hospital
RECRUITINGAomori, Japan
-
Akita Prefectural Center For Rehabilitation and Psychiatric Medicine
RECRUITINGAkita, Japan
-
Asuka Hospital
RECRUITINGTokyo, Japan
-
Fujisawahospital
RECRUITINGKanagawa, Japan
-
Fukui Hospital
RECRUITINGFukui, Japan
-
Hatano Kousei Hospital
RECRUITINGKanagawa, Japan
-
Hayakawa Clinic
RECRUITINGHiroshima, Japan
-
Hizen Psychiatric Center
RECRUITINGSaga, Japan
-
Hosogi Hospital
RECRUITINGKochi, Japan
-
Hotei Hospital
RECRUITINGAichi, Japan
-
Ichiyo Mental Hospital
RECRUITINGKochi, Japan
-
Iryohojin Shadan Shoshinkai Morinohosupitaru・Aoba
RECRUITINGMiyagi, Japan
-
Ishiki Hospital
RECRUITINGKagoshima, Japan
-
JA-Nagano North Alps Medical Center Azumi Hospital
RECRUITINGNagano, Japan
-
Jizenkai Ando Hospital
RECRUITINGNagano, Japan
-
Keiseikai Hospital
RECRUITINGHokkaido, Japan
-
Kishikai Kishi Hospital
RECRUITINGGunma, Japan
-
Koseikai Cocoro Hospital Kusatsu
RECRUITINGHiroshima, Japan
-
Kuramitsu Hospital
RECRUITINGFukuoka, Japan
-
Maizuru Medical Center
RECRUITINGKyoto, Japan
-
Matsubara Hospital
RECRUITINGFukui, Japan
-
Medical Corporation Keishinkai Kyowa Hospital
RECRUITINGAkita, Japan
-
NHO Obihiro National Hospital
RECRUITINGHokkaido, Japan
-
Nagaokai Neyagawa Sanatorium
RECRUITINGOsaka, Japan
-
Nakamura Hospital
RECRUITINGHiroshima, Japan
-
Nara Medical University Hospital
RECRUITINGNara, Japan
-
Nishigahara Hospital
RECRUITINGTokyo, Japan
-
Nishiyama Hospital
RECRUITINGKyoto, Japan
-
Osaka Institute of Clinical Psychiatry Shin-Abuyama Hospital
RECRUITINGOsaka, Japan
-
Rainbow & Sea Hospital
RECRUITINGSaga, Japan
-
Saitama Konan Hospital
RECRUITINGSaitama, Japan
-
Sansyu Hospital
RECRUITINGKagoshima, Japan
-
Sanyokai Sanyo Hospital
RECRUITINGYamagata, Japan
-
Seinan Hospital
RECRUITINGAomori, Japan
-
Showa Medical University Northern Yokohama Hospital
RECRUITINGKanagawa, Japan
-
Taniyama Hospital
RECRUITINGKagoshima, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ONO-2020 (an experimental oral drug)
What this could lead to
If it works, this could provide a new treatment option to reduce agitation in people with Alzheimer's dementia, improving their quality of life and easing caregiver burden.
What could go wrong
This is an early phase 2a trial with only 90 participants in Japan, so results may not apply broadly. The drug may prove no better than placebo, or side effects could limit its use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.